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Background: Diabetic nephropathy (DN) is one of the major complications of diabetes. 
Hyperglycemia, inflammation and oxidative stress as well as advanced glycation end 
products (AGEs) are reported as the risk factors for DN. Sevelamer has shown promising 
results in reducing inflammation and even HbA1c levels in DN. 
Objectives: We aimed to evaluate the therapeutic effects of sevelamer on blood sugar, HbA1c 
level, lipid profile, and high sensitivity C-reactive protein (hs-CRP) in patients with DN. 
Patients and Methods: In this clinical trial, 18 patients (5 males and 13 females with mean 
age of 61.22±9.32 years) with stages 2-4 of DN were recruited. Patients were administered 
with 800 mg of sevelamer twice a day for 3 months. Blood sugar, HbA1c, hs-CRP, lipid 
profile and other laboratory findings were measured before and 1, 2 and 3 months after 
initiation of the treatment. 
Results: There was a significant decline in HbA1c (P = 0.001), postprandial blood sugar 
(P <0.001) and phosphorus (P < 0.001) at the end of the study period. Sevelamer had no 
effect on fasting blood sugar, lipid profile, blood urea nitrogen (BUN), creatinine, Na, K 
and hs-CRP.  
Conclusions: Our results indicated that along with its phosphorus reducing effects, sevelamer 
plays an important role in decreasing postprandial blood sugar and HbA1c level. Sevelamer 
had no effects on lipid profile and hs-CRP.
ABSTRACT
Implication for health policy/practice/research/medical education:
Hyperglycemia, inflammation and oxidative stress as well as advanced glycation end products (AGEs) are reported risk factors 
of  diabetic nephropathy (DN). Besides phosphorus reducing effects, sevelamer could decrease postprandial blood sugar and 
HbA1c level. Sevelamer had no effects on lipid profile and high sensitivity CRP.
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1. Background
Diabetic nephropathy (DN) is one of  the major 
microvascular complications of  diabetes and has become 
the leading cause of  end-stage renal disease (ESRD) (1,2). 
DN is also a major cause of  morbidity and mortality in 
patients with diabetes due to the progression to ESRD 
and associated cardiovascular disease (3,4).
Hyperglycemia, inflammation and oxidative stress 
are reported as the risk factors for the induction and 
progression of  DN (3,4). Along with these factors, 
advanced glycation end products (AGEs) are another 
factor which cause the increase of  inflammatory markers 
and oxidative stresses which can result in the progress of 
chronic kidney disease (CKD) (5). Various studies have 
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indicated that enhancing oxidative stress and chronic 
vascular inflammation exacerbates the prognosis of 
nephropathy in type II diabetic patients (5-7).
Sevelamer is a non-absorbable calcium and aluminum-
free phosphate binder which attaches to phosphorus 
in the intestine preventing its absorption and causing a 
decrease in the total phosphorus level (8). It is shown 
that serum phosphorus is independently correlated 
with inflammatory parameters (9), and using sevelamer 
could reduce the inflammation and hs-CRP level by 
reducing the phosphorus levels (10). A recent study has 
also indicated that sevelamer has significant effects on 
hemoglobin A1C (HbA1c) and markers of  inflammation 
in patients with DN (5).
2. Objectives
As there are no related studies in Iran, we aimed to 
evaluate the therapeutic effects of  sevelamer on blood 
sugar, HbA1c, Lipid profiles, and hs-CRP in patients 
with DN. 
3. Patients and Methods 
3.1. Patients
In this clinical trial, we recruited 18 patients with DN 
visiting nephrology clinics of  Imam-Khomeini hospital, 
Ardabil, Iran. Inclusion criteria were DN stage 2-4, age 
≥46 years and sugar level of  100-400 mg/dL. Patients 
with current treatment for hyperphosphatemia, biopsy-
proven renal disease other than diabetic kidney disease, 
hypophosphatemia, hypercalcemia, symptomatic 
gastrointestinal disorders and concomitant inflammatory 
diseases were excluded. 
3.2. Intervention and biochemical measurement
Patients were assigned to receive sevelamer (800 mg twice 
a day) for 12 weeks. Patients received all their previous 
medications and we made no changes in medications or 
their diets. 
HbA1c and lipid profile was measured before and at the 
end of  the study. Other laboratory findings including 
Ca, P, hs-CRP, fasting and postprandial blood sugar and 
CBC with differential were measured before and at first, 
second and third months after the study initiation. 
3.3. Ethical issues
The research followed the tenets of  the Declaration of 
Helsinki. The study protocol was approved by the ethics 
committee of  the Ardabil University of  Medical Science 
and all participants gave written informed consent before 
enrolling in the study. Besides that, the study proto col 
was registered as In the Iranian Registry of  Clinical Trials 
(identifier: IRCT2016100423559N5; http://en.search.
irct.ir/view/33110).
3.4. Statistical analysis
All data were analyzed using SPSS20 (version 20; SPSS 
Inc., Chicago, IL). Results are expressed as mean ± 
standard deviation or percentage. Paired samples t test 
and repeated measure of  analysis of  variance (ANOVA) 
were used to evaluate the changes in the variables during 
the study period and P values   of  less than 0.05 were 
considered statistically signif i cant. 
4. Results
The study population comprised of  5 males (27.8%) 
and 13 females (72.2%) with a mean age of  61.22± 9.32 
years (range 46-77 years). The mean body mass index 
was 28.64 ± 1.97 kg/m2. 
Changes in HbA1c and lipid profile are shown in Table 
1. HbA1c was significantly declined following the 
treatment, but the changes in cholesterol, triglyceride, 
high-density lipoprotein (HDL-C) and low-density 
lipoprotein (LDL-C) levels were not significant.
Sevelamer had significantly decreased phosphorus 
levels (Table 2). There was also a significant decrease in 
postprandial blood sugar, while it did not affect fasting 
blood sugar. Also, there were no changes in blood urea 
nitrogen (BUN), creatinine, sodium, potassium and 
calcium levels. 
5. Discussion
In this study, we evaluated the therapeutic effects of 
sevelamer in patients with DN stage 2-4 and observed 
that sevelamer significantly reduced HbA1c and 
postprandial blood sugar. 
Similar to our findings, Vlassara et al (5) found that 
treatment with sevelamer can reduce HbA1c levels. 
Table 1. HbA1c levels and lipid profile before and after study
Before the study 3 Months later P value
HbA1c (%) 7.92±1.41 6.99±1.96 0.001
Triglyceride (mg/ dL) 184.89±80.77 177.44±80.40 0.54
Cholesterol (mg/ dL) 178.78±44.49 168.39±41.76 0.2
HDL-C (mg/ dL) 48.17±7.68 47.89±7.44 0.7
LDL-C (mg/dL) 94.61±40.57 85.56±30.71 0.32
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While in another study by Yubero-Serrano and 
colleagues (11), HbA1c was not significantly reduced in 
overall population, but had significant changes in female 
patients. It is suggested a direct association between 
AGEs and insulin resistance, as by reduction of  AGEs, 
the resistance is decreased and may result in better glucose 
hemostasis (12). Considering the effects of  sevelamer 
on reducing AGEs, it is possible that sevelamer could 
improve glucose tolerance and reduce HbA1c, beside its 
phosphorus reducing effects (5).
Our results indicated that the consumption of  sevelamer 
does not affect lipid profile in DN patients. This finding is 
partially in line with the findings of  the study conducted 
by Ahmadi et al (13) in which they studied hemodialysis 
patients and found that sevelamer decreases triglycerides 
levels but does not affect their LDL-C, HDL-C, and total 
serum cholesterol. However, our finding regarding the 
patients’ lipid profile was inconsistent with the findings 
of  the studies conducted by Chertow et al (14), Shantouf 
et al (15) and Burke et al (16). Additionally, in the 
study of  Vlassara et al (5) on DN patients, they found 
significant lipid lowering effects on triglycerides and total 
cholesterol, but no changes in HDL-C and LDL-C levels. 
Sevelamer had no effects on inflammatory marker, hs-
CRP, in our study. While previous studies have reported 
sevelamer could reduce circulating hs-CRP in patients 
with CKD and on dialysis (10,15-18). The two other 
studies evaluating the effects of  sevelamer in DN patients 
have also shown significant inflammation lowering and 
reducing oxidative stress effects for sevelamer (5,11). The 
differences in proportion of  samples in each study and 
the duration of  the treatment could be a cause for these 
observed differences.
6. Conclusions
In conclusion, the addition of  sevelamer to the treatment 
of  patients with DN resulted in reduction of  HbA1c and 
postprandial blood sugar levels, beside their phosphorus 
lowering benefits. Sevelamer showed no significant 
effects on lipid profile and hs-CRP. However, these 
results must be confirmed by larger and longer duration 
of  therapy trials.
Study limitations
The present study is limited in several aspects. First, the 
proportion of  patients in this study was relatively small, 
limiting its statistical power. This was a single center 
nonrandomized with no control group study, hence it has 
its inherent limitations. We also did not measure AGEs 
levels in our patients to evaluate sevelamer effects. Also, 
short duration of  the intervention is another limitation 
of  the study.
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Table 2. Electrolytes, CBC and hs-CRP changes during the study
 At baseline 1st month 2nd month 3rd month P value
Hemoglobin (g/dL) 12.06±1.11 12.04±1.00 12.05±0.89 12.04±1.45 0.93
WBC (/mm3) 7820.56±2072.47 8369.44±1923.01 8322.22±1852.68 8380.00±2316.42 0.29
Platelet (×106)/ mm3 232.44±74.40 234.41±75.69 219.55±67.15 223.33±72.63 0.29
FBS (mg/dL) 154.78±85.99 144.06±82.37 143.67±84.28 135.89±86.70 0.27
Postprandial BS (mg/dL) 236.94±86.12 206.89±76.55 197.28±75.82 191.56±90.64 <0.001
BUN (mg/ dL) 84.22±38.30 77.11±37.00 79.33±42.19 75.56±36.78 0.21
Creatinine (mg/dL) 2.07±0.81 2.04±0.88 1.97±0.83 1.99±0.93 0.6
Na (mEq/L) 139.50±28.9 139.17±3.45 139.17±3.50 139.17±3.97 0.9
K (mEq/L) 4.43±0.67 4.48±0.65 4.43±0.57 4.26±0.66 0.57
Ca (mg/dL) 9.92±0.31 9.71±0.24 9.43±0.57 9.83±0.44 0.55
P (mg/dL) 4.95±0.58 4.92±0.63 4.75±0.77 4.22±0.82 <0.001
hs-CRP (mg/L) 2.61±1.66 2.65±0.92 2.55±0.92 2.56±1.90 0.88
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